Data Mining in Pharmacovigilance Manfred HaubenDavid MadiganDonald J. O’Hara Commentary 24 August 2012 Pages: 319 - 323
The Impact of the Web and Standards on Clinical Trials David Iberson-Hurst Commentary 24 August 2012 Pages: 325 - 330
Is it Time to Revisit the Current R&D Model? Damian O’ConnellAndrew HopkinsDavid Roblin Current Opinion 24 August 2012 Pages: 339 - 345
Improving Decision-Making in Drug Development Using In Vitro Toxicology Screening Willi Suter Current Opinion 24 August 2012 Pages: 347 - 355
Safety Pharmacology Assessment Brian D. GuthPeter K. S. Siegl Current Opinion 24 August 2012 Pages: 357 - 361
Drug Cost Development of Citalopram and Fluoxetine Following the Introduction of Generic Substitution in Finland Ville Aalto-SetäläRisto KanervaJ. Simon Bell Original Research Article 24 August 2012 Pages: 363 - 368